Research Program: Women's Cancer
Associate Professor, Department of Experimental and Clinical Pharmacology

kirst002@umn.edu
612-624-5689 — office
612-624-8455 — lab
Preferred method of contact: e-mail or office phone

Dr. Kirstein is an associate professor in the College of Pharmacy's Department of Experimental and Clinical Pharmacology. From 1999 to 2001, he was a research fellow under the mentorship of Clinton Stewart, Pharm.D., in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital in Memphis. He received his Pharm.D. in 1999 from the University of Tennessee in Memphis.

Research Interests

Clinical pharmacology of anticancer agents — Optimizing chemotherapy administration through assessment of drug pharmacokinetics in human subjects; the role of pharmacogenetics in treatment outcomes (toxicity, antitumor activity).

Preclinical pharmacology of anticancer agents — Optimizing chemotherapy administration through assessment of optimal drug exposure and scheduling of combination regimens using tissue culture models and the bioreactor system.

Selected Publications

Dudek AZ, Pawlak WZ, Kirstein MN. Molecular Targets in the Inhibition of Angiogenesis. Expert Opin Ther Targets 2003;7:527-541.

Kirstein MN, Panetta JC, Gajjar A, Nair G, Iacono L, Freeman B, Stewart C. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemother Pharmacol. 2005;55:433-438.

Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Cancer Invest, 23(6):511-19, 2005.

Kirstein MN, Brundage RC, Elmquist WF,Remmel RP, Marker PH, Guire DE, Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat. 2006;96:217-225.

Kirstein MN, Guire DE, Weller DR, Dagit JW, Fisher J, Remmel RP. High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835:136-142.

Kirstein MN, Moore MM, Dudek AZ. Targeted therapy of tumor angiogenesis: Review of selected recent patents for angiogenesis therapy of cancer. Recent Patent Reviews on Anti-Cancer Drug Discovery; 1: 153-61, 2006.

Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D, Kratzke RA. Short vs. Continuous infusion gemcitabine in an in vitro cell culture bioreactor system. Lung Cancer, 58(2):196-204, 2007

Kirstein MN, Brundage RC, Moore MM, Hillman LA, Marker PH, Kratzke R, Yee D. Pharmacodynamic characterization of gemcitabine cytotoxicity in the in vitro cell culture bioreactor system. Cancer Chemotherapy and Pharmacology, 61(2):291-9, 2008.

Kirstein MN, Root SA, Moore MM, Wieman KM, Williams BW, Jacobson PA, Marker PH, Tuttle TM. Exposure-response relationships for oxaliplatin treated colon cancer cells. Anti-Cancer Drugs, 19(1):37-44, 2008.

Williams BW, Chang JJ, Chi RM, Marker PH, Frethem CD, Le CT, Kratzke RA, and Kirstein MN. Cap-dependent translation blockade and fixed dose-rate gemcitabine: Interaction in an in vitro bioreactor system. Cancer Letters, In Press.